Last reviewed · How we verify
HL-1186
At a glance
| Generic name | HL-1186 |
|---|---|
| Sponsor | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery (PHASE2)
- Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery (PHASE2)
- Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain (PHASE2)
- Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HL-1186 CI brief — competitive landscape report
- HL-1186 updates RSS · CI watch RSS
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. portfolio CI